Aequus and reVision to Collaborate on Stargardt Disease Program using SBECD as active
Aequus Pharmaceuticals Inc. and reVision Therapeutics, Inc. (“reVision”) announced a collaboration on the development of a therapy for Stargardt disease.
Tag: ophthalmology
Clinical trial: Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
CBT-006 is a molecule developed by Cloudbreak Therapeutics that can sequester cholesterol. CBT-006 is a unique topical formulation following 505b(2)
OCULIS ANNOUNCES AN OVERSUBSCRIBED US$57 MILLION SERIES C FINANCING
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
New cyclodextrin with orphan drug designation: SBECD
ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular
Oculis started Phase II clinical trial with OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced